We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Merck Czech Republic

Pharmaceutical > Czech Republic > Merck Czech Republic
Change Company
Merck Czech Republic

Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company is a global health care player that delivers health solutions through its prescription

Read more »
Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company is a global health care player that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures

Buy all financials of Merck Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
...                   1,622 1,755 1,726 1,798 1,850    
...                   232 230 184 201 263    
...                   65.9 82.5 48.2 52.6 94.7    
...                   49.3 63.4 27.4 34.9 68.6    
...                   24.6% 24.7% 9.05% 10.5% 17.8%    
...                   4.06% 4.70% 2.79% 2.93% 5.12%    
...                   3.04% 3.62% 1.59% 1.94% 3.71%    
                    131 119 113 112 107    

balance sheet

...                   445 500 544 476 530    
...                   10.1 9.11 8.11 5.62 6.32    
...                   432 488 534 469 523    
...                   225 289 316 351 419    
...                   219 211 228 125 111    
...                   0.000 0.000 0.000 0.000 0.000    
...                   196 187 200 91.9 78.7    
...                   1.87 1.39 2.80 0.353 -0.026    
...                   55.8% 40.2% 43.6% 5.40% -0.588%    
... ...                 4.81% 8.10% 4.56% 7.78% 68.8% ... ...

cash flow

... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    

Download Data
income statement Unit
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
Dividends CZK mil
...                   1,622 1,755 1,726 1,798 1,850    
...                   1,389 1,525 1,542 1,597 1,587    
...                   232 230 184 201 263    
...                   132 150 130 138 156    
...                   33.5 -3.66 5.39 8.86 11.1    
...                   67.1 83.8 49.2 53.6 95.9    
...                   1.22 1.23 0.998 1.03 1.17    
...                   65.9 82.5 48.2 52.6 94.7    
...                   6.13 10.7 6.12 6.50 7.49    
...                   0.000 0.000 0.000 0.000 0.000    
...                   59.7 71.8 42.1 46.1 87.2    
...                   10.5 8.39 14.7 11.2 18.6    
...                   0.000 0.000 0.000 0.000 0.000    
...                   49.3 63.4 27.4 34.9 68.6    
    ...   ...   ... ... ... ... ... ... ... ... ... ... ...

growth rates

... ...                 17.9% 8.18% -1.61% 4.15% 2.88%    
... ...                 147% -11.7% -7.57% 9.06% 13.5%    
... ...                 170% 24.9% -41.2% 8.97% 78.8%    
... ...                 182% 25.3% -41.6% 9.10% 80.1%    
... ...                 208% 20.3% -41.4% 9.51% 89.2%    
... ...                 321% 28.7% -56.9% 27.5% 96.7%    

ratios

...                   24.6% 24.7% 9.05% 10.5% 17.8%    
... ...                 13.7% 14.8% 5.72% 7.46% 15.7%    
...                   14.3% 13.1% 10.7% 11.2% 14.2%    
...                   4.14% 4.77% 2.85% 2.98% 5.18%    
...                   4.06% 4.70% 2.79% 2.93% 5.12%    
...                   3.04% 3.62% 1.59% 1.94% 3.71%    
...   ...   ...   ... ... ... ... ... ... ... ... ... ... ...
... ...                 4.81% 8.10% 4.56% 7.78% 68.8% ... ...
...                   1.87 1.39 2.80 0.353 -0.026    

Download Data
balance sheet Unit
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

balance sheet

...                   10.1 9.11 8.11 5.62 6.32    
...                   9.25 8.45 7.65 5.36 6.06    
...                   0.851 0.659 0.459 0.258 0.261    
...                   432 488 534 469 523    
...                   189 219 246 244 240    
...                   213 252 266 204 210    
...                   15.6 6.95 7.67 2.83 2.47    
...                   445 500 544 476 530    
...                   225 289 316 351 419    
...                   0.000 0.000 0.000 0.000 0.000    
...                   219 211 228 125 111    
...                   0.000 0.000 0.000 0.000 0.000    
...                   0.000 0.000 0.000 0.000 0.000    
...                   0.000 0.000 0.000 0.000 0.000    
...                   196 187 200 91.9 78.7    
...                   141 123 145 21.8 0.000    
...                   12.6 22.5 20.1 17.8 15.8    
...                   23.1 23.9 28.4 33.3 31.8    
...                   445 500 544 476 530    

growth rates

... ...                 25.8% 12.5% 8.86% -12.5% 11.3%    
... ...                 28.0% 28.2% 9.48% 11.0% 19.6%    
... ...                 13.5% -7.53% 18.5% -86.2% -113%    
... ...                 24.2% -12.8% 18.1% -85.0% -100% ... ...

ratios

...                   141 123 145 21.8 0.000    
...                   126 116 138 18.9 -2.47    
...                   389 449 491 430 434    
...                   399 458 499 436 441    
...                   55.8% 40.2% 43.6% 5.40% -0.588%    
... ...                 4.81% 8.10% 4.56% 7.78% 68.8% ... ...

Download Data
cash flow Unit
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

cash flow

...                   49.3 63.4 27.4 34.9 68.6    
...                   1.22 1.23 0.998 1.03 1.17    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    

ratios

...                   47.8 52.4 56.1 41.3 41.4    
...                   49.6 52.5 58.2 55.8 55.3    
...                   3.30 5.39 4.75 4.07 3.63    
...                   94.1 99.5 110 93.1 93.1    
...                   50.5 64.7 28.4 35.9 69.8    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    

Download Data
other data Unit
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017

other data

...                   12.4% 13.4% 5.24% 6.84% 13.6%    
...                   14.3% 13.1% 10.7% 11.2% 14.2%    
                    131 119 113 112 107    
...                   4,745 5,361 4,886 4,818 5,091    
...                   83,921 104,854 95,599 102,967 121,529    
...                   8.48% 8.96% 7.72% 7.93% 8.89%    
...                   17.5% 11.7% 35.0% 24.4% 21.3%    
... ... ... ... ... ... ... ... ... ... ... ... ... ... ...    
                    303 384 346 373 391    
                    1,038 1,115 1,145 1,186 1,228    
                    271 247 222 225 223    

Download Data
Comparison of 9 Companies in Czech Pharmaceutical Companies

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file

Read more »

This Annual Statistical Dossier offers a comparison of 9 companies from Czech Pharmaceutical Companies from 2000 to 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

The file contains data of following companies:

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

Download a sample excel file attached to see more details. On purchase, the hidden cells will be unlocked and all available data wll be visible.

Merck Czech Republic in Numbers

This Annual Statistical Dossier offers a summary of Merck Czech Republic's performance between 2001 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested

Read more »

This Annual Statistical Dossier offers a summary of Merck Czech Republic's performance between 2001 and 2017 on an annual basis. The report can be downloaded as an Excel file.

You will find here the key numbers from the company's balance sheet, income statement, cash flow and the main ratios related to the firm's business.

If you are only interested in particular areas of the company's business, you can find and download specific indicators from the company's Corporate Profile, or specific charts from the company's Chart Section.

If you are interested in the company’s quarterly figures, please refer to the company’s Quarterly Statistical Dossier.

Merck Czech Republic at a Glance

Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company

Read more »

Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company is a global health care player that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

This report offers a summary of the company's performance in 2002-2013. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Merck Czech Republic in Numbers

Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company

Read more »

Merck spol. s r.o. (or Merck Czech Republic) is a Czech Republic-based subsidiary of Merck & Co. The Czech subsidiary was founded in 1991 and is involved in marketing , sale and distribution of pharmaceutical and chemical products. Merck & Co is the oldest pharmaceutical and chemical company in the world. Its roots date back to the year 1668. Now, the Company is a global health care player that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

This excel file offers a summary of the company's performance in 2002-2013. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Merck Czech Republic made a net profit of CZK 50.5 mil in 2017, up 21.7% when compared to the last year. Total sales reached CZK 1,818 mil, which is down 0.149% when compared to the previous year.

Historically, the company’s

Read more »

Merck Czech Republic made a net profit of CZK 50.5 mil in 2017, up 21.7% when compared to the last year. Total sales reached CZK 1,818 mil, which is down 0.149% when compared to the previous year.

Historically, the company’s net profit reached an all time high of CZK 68.6 mil in 2015 and an all time low of CZK 1.98 mil in 2008.

In terms of sales, Merck Czech Republic reached an all time high of CZK 1,850 mil in 2015 and an all time low of CZK 514 mil in 2003.

Merck Czech Republic's net profit has grown -4.44% a year on average in the last five years while sales have increased by 0.715% a year since 2012.

The firm generated its shareholders an average return on invested capital of 8.69% in the last five years.

As far as Merck Czech Republic's peers are concerned, Bayer Czech Republic posted a net profit and sales of CZK 106 mil and CZK 4,180 mil in 2017 and Amgen Czech Republic generated a net profit of CZK 37.8 mil (with sales of CZK 417 mil).

You can see all the company’s data at Merck Czech Republic Profile, or you can download a report on the company in the report section.

Merck Czech Republic made a net profit of CZK CZK 50.5 mil under revenues of CZK 1,818 mil in 2017, up 21.7% and -0.149%, respectively, when compared to the last year.

This translates into a net margin of 2.78%. Historically,

Read more »

Merck Czech Republic made a net profit of CZK CZK 50.5 mil under revenues of CZK 1,818 mil in 2017, up 21.7% and -0.149%, respectively, when compared to the last year.

This translates into a net margin of 2.78%. Historically, the firm’s net margin reached an all time high of 9.68% in 2006 and an all time low of 0.160% in 2008. The average net margin in the last five years amounted to 2.46%.

On the operating level, EBITDA margin reached 3.92% and EBIT amounted to 4.00% of sales in 2017.

As far as Merck Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Merck Czech Republic Profile, or you can download a report on the company in the report section.

Merck Czech Republic made a net profit of CZK 50.5 mil under revenues of CZK 1,818 mil in 2017, up 21.7% and -0.149%, respectively, when compared to the last year. This translates into a net margin of 2.78%.

Historically, the

Read more »

Merck Czech Republic made a net profit of CZK 50.5 mil under revenues of CZK 1,818 mil in 2017, up 21.7% and -0.149%, respectively, when compared to the last year. This translates into a net margin of 2.78%.

Historically, the firm’s net profit reached an all time high of CZK 68.6 mil in 2015 and an all time low of CZK 1.98 mil in 2008. Since 2012, the firm's net profit has increased -20.3% or -4.44% a year on average.

On the operating level, EBITDA reached CZK 72.8 mil, up 19.6% when compared to the previous year. Over the last five years, company's EBITDA has grown -2.77% a year on average.

As far as Merck Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.53% and 3.77%, respectively in 2017 and Amgen Czech Republic generated margins of 9.06% and 11.8%.

You can see all the company’s data at Merck Czech Republic Profile, or you can download a report on the company in the report section.

Merck Czech Republic's net debt reached CZK -25.1 mil and accounted for -3.73% of equity at the end of 2017. The ratio is up 14.2% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all

Read more »

Merck Czech Republic's net debt reached CZK -25.1 mil and accounted for -3.73% of equity at the end of 2017. The ratio is up 14.2% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 230% in 2008 and an all time low of -7.82% in 2003.

When compared to EBITDA, net debt amounted to -0.345x at the end of the year. The ratio reached an all time high of 26.1 in 2008 and an all time low of -0.445 in 2016.

As far as Merck Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 94.4%x and 2.49x when compared to EBITDA at the end of 2017. Amgen Czech Republic ended the year 2017 with a net debt at -0.147%x of equity and -0.006x when compared to its EBITDA while Amgen Czech Republic had net debt at -0.147%x of equity and -0.006x to EBITDA at the end of the year.

You can see all the company’s data at Merck Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »
Merck CR's net profit rose 21.7% to CZK 50.5 mil in 2017
Merck CR's net profit rose 21.7% to CZK 50.5 mil in 2017
Merck CR's employees fell 1.83% to 107 in 2017
Merck CR's Net Debt/EBITDA rose 22.5% to -0.345 in 2017
Merck CR's Cash & Cash Equivalents fell 7.29% to CZK 25.1 mil in 2017
Merck CR's ROCE fell 3.32% to 7.18% in 2017
Merck CR's Net Margin rose 21.9% to 2.78% in 2017